JP2021513540A5 - - Google Patents
Info
- Publication number
- JP2021513540A5 JP2021513540A5 JP2020542952A JP2020542952A JP2021513540A5 JP 2021513540 A5 JP2021513540 A5 JP 2021513540A5 JP 2020542952 A JP2020542952 A JP 2020542952A JP 2020542952 A JP2020542952 A JP 2020542952A JP 2021513540 A5 JP2021513540 A5 JP 2021513540A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence shown
- cancer
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000161A JP2024038250A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862630038P | 2018-02-13 | 2018-02-13 | |
| US62/630,038 | 2018-02-13 | ||
| US201862732828P | 2018-09-18 | 2018-09-18 | |
| US62/732,828 | 2018-09-18 | ||
| US201862740741P | 2018-10-03 | 2018-10-03 | |
| US62/740,741 | 2018-10-03 | ||
| PCT/US2019/017188 WO2019160755A1 (en) | 2018-02-13 | 2019-02-08 | Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000161A Division JP2024038250A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021513540A JP2021513540A (ja) | 2021-05-27 |
| JP2021513540A5 true JP2021513540A5 (https=) | 2022-09-08 |
| JPWO2019160755A5 JPWO2019160755A5 (https=) | 2022-09-08 |
Family
ID=67620098
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542952A Pending JP2021513540A (ja) | 2018-02-13 | 2019-02-08 | 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
| JP2024000161A Withdrawn JP2024038250A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000161A Withdrawn JP2024038250A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210047409A1 (https=) |
| EP (1) | EP3752193A4 (https=) |
| JP (2) | JP2021513540A (https=) |
| KR (1) | KR20200119845A (https=) |
| CN (2) | CN119792515A (https=) |
| AU (2) | AU2019222517A1 (https=) |
| BR (1) | BR112020015915A8 (https=) |
| CA (1) | CA3090996A1 (https=) |
| MA (1) | MA51844A (https=) |
| MX (1) | MX2020008446A (https=) |
| WO (1) | WO2019160755A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| EP3937979A4 (en) * | 2019-03-13 | 2023-03-08 | Merck Sharp & Dohme LLC | COMBINATIONAL ANTI-CANCER THERAPIES WITH CTLA-4 AND PD-1 BLOCKING AGENTS |
| CN113244385A (zh) * | 2020-02-07 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗恶性肿瘤中的用途 |
| EP4114863A4 (en) * | 2020-03-05 | 2024-04-24 | Merck Sharp & Dohme LLC | METHODS OF TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-CTLA4 ANTIBODY AND AN ANTI-TIGIT ANTIBODY |
| EP4114464A4 (en) * | 2020-03-05 | 2024-05-01 | Merck Sharp & Dohme LLC | Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof |
| WO2021213523A1 (zh) * | 2020-04-24 | 2021-10-28 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 |
| TW202305009A (zh) * | 2021-04-08 | 2023-02-01 | 美商默沙東有限責任公司 | 以皮下投予抗pd1抗體治療癌症之方法 |
| MX2024000406A (es) * | 2021-07-19 | 2024-04-18 | Regeneron Pharma | Combinacion de inhibidores de puntos de control y un virus oncolitico para el tratamiento del cancer. |
| CN118176021A (zh) * | 2021-10-29 | 2024-06-11 | 昂科医药 | 抗ctla-4抗体给药方案 |
| CN113933520B (zh) * | 2021-11-15 | 2023-06-20 | 邹灵龙 | 一种通用型抗体药血药浓度检测的单克隆抗体试剂组合、检测方法和试剂盒 |
| WO2024002074A1 (zh) * | 2022-06-28 | 2024-01-04 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| WO2024055005A2 (en) * | 2022-09-09 | 2024-03-14 | Adagene Pte. Ltd. | Activatable anti-ctla4 antibodies for treating cancer |
| AU2024251723A1 (en) * | 2023-04-10 | 2025-11-27 | Akeso Pharma Co., Ltd. | Medical use of anti-ctla4 and anti-pd-1 bispecific antibody |
| WO2025042997A1 (en) * | 2023-08-21 | 2025-02-27 | Agenus Inc. | Methods of treating colorectal cancer using a combination of a ctla-4 inhibitor and a pd-1 inhibitor |
| CN121712807A (zh) * | 2023-08-31 | 2026-03-20 | 江苏恒瑞医药股份有限公司 | Ctla4/tigit结合蛋白及其医药用途 |
| WO2026021409A1 (zh) * | 2024-07-22 | 2026-01-29 | 宜明昂科生物医药技术（上海）股份有限公司 | 靶向ctla-4、pd-l1和vegf的肿瘤联合疗法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL148079A0 (en) * | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| RU2494107C2 (ru) * | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| HRP20131167T1 (hr) * | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| AR095199A1 (es) * | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| CA2955676A1 (en) * | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| US20160362489A1 (en) * | 2015-04-28 | 2016-12-15 | Bristol-Myers Squibb Company | Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody |
| JP2018522887A (ja) * | 2015-07-14 | 2018-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| WO2017021911A1 (en) * | 2015-08-04 | 2017-02-09 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| EP3331919A1 (en) * | 2015-08-07 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy comprising anti ctla-4 antibodies |
| WO2017106656A1 (en) * | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| US10358496B2 (en) * | 2016-03-01 | 2019-07-23 | Ralf Kleef | Low dose immune checkpoint blockade in metastatic cancer |
| LT3463457T (lt) * | 2016-06-02 | 2023-09-11 | Bristol-Myers Squibb Company | Pd-1 blokada su nivolumabu gydant atsparią hodžkino limfomą |
| WO2017210624A1 (en) * | 2016-06-03 | 2017-12-07 | Bristol-Myers Squibb Company | Anti-pd-1 antibody for use in a method of treating a tumor |
| WO2017210637A1 (en) * | 2016-06-03 | 2017-12-07 | Bristol-Myers Squibb Company | Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer |
| SG11201910134SA (en) * | 2017-05-02 | 2019-11-28 | Merck Sharp & Dohme | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
-
2019
- 2019-02-08 EP EP19754385.3A patent/EP3752193A4/en active Pending
- 2019-02-08 CN CN202510115562.9A patent/CN119792515A/zh active Pending
- 2019-02-08 AU AU2019222517A patent/AU2019222517A1/en not_active Abandoned
- 2019-02-08 CN CN201980013384.1A patent/CN111727056A/zh active Pending
- 2019-02-08 MA MA051844A patent/MA51844A/fr unknown
- 2019-02-08 KR KR1020207026005A patent/KR20200119845A/ko not_active Withdrawn
- 2019-02-08 BR BR112020015915A patent/BR112020015915A8/pt unknown
- 2019-02-08 CA CA3090996A patent/CA3090996A1/en active Pending
- 2019-02-08 US US16/966,988 patent/US20210047409A1/en active Pending
- 2019-02-08 JP JP2020542952A patent/JP2021513540A/ja active Pending
- 2019-02-08 WO PCT/US2019/017188 patent/WO2019160755A1/en not_active Ceased
- 2019-02-08 MX MX2020008446A patent/MX2020008446A/es unknown
-
2023
- 2023-07-26 AU AU2023208115A patent/AU2023208115A1/en active Pending
-
2024
- 2024-01-04 JP JP2024000161A patent/JP2024038250A/ja not_active Withdrawn